TITLE

An abnormal D-dimer test result indicated that anticoagulation should be continued

PUB. DATE
March 2007
SOURCE
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p29
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article cites a research study focusing on the patients with a first episode of venous thromboembolism (VTE), who had received vitamin-K antagonists. An abnormal D-dimer test conducted on these patients indicated that anticoagulation therapy of theses patients should be continued. Patients with abnormal D-dimer levels, who did not resume anticoagulation had confirmed recurrent VTE or major bleeding events than those who resumed anticoagulation.
ACCESSION #
24685652

 

Related Articles

  • Warfarin Overdose: A 25-Year Experience. Levine, Michael; Pizon, Anthony; Padilla-Jones, Angela; Ruha, Anne-Michelle // Journal of Medical Toxicology;Jun2014, Vol. 10 Issue 2, p156 

    Warfarin, a vitamin K antagonist, is widely used for the prophylaxis and treatment of thromboembolic disease. While guidelines exist for management of a supratherapeutic international normalized ratio following therapeutic warfarin use, these guidelines are not designed for management of the...

  • Vitamin K KO'd by Placebo for Overanticoagulation.  // Clinician Reviews;Apr2009, Vol. 19 Issue 4, p28 

    The article discusses research being done on vitamin K. It references a study by M. A. Crowther et al that was published in a 2009 issue of "Annals of Internal Medicine." The study found that in a head-to-head comparison with placebo, low-dose oral vitamin K did not effectively reduce bleeding...

  • COMMENTARY: An abnormal D-dimer test result indicated that anticoagulation should be continued. Crowther, Mark // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p29 

    The article comments on a research study focusing on the patients with a first episode of venous thromboembolism (VTE), who had received vitamin-K antagonists. The author opines that despite some limitations, this study is an important step in the refinement of anticoagulation care for patients...

  • 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Eischer, L.; Gartner, V.; Schulman, S.; Kyrle, P. A.; Eichinger, S. // Annals of Hematology;May2009, Vol. 88 Issue 5, p485 

    Patients with first venous thromboembolism (VTE) and high factor VIII (FVIII) are at increased risk of recurrence. It is unknown whether these patients benefit from prolonged secondary thrombophrophylaxis. In a prospective trial patients with first spontaneous VTE and FVIII levels >230 IU/dl...

  • Vitamin K in the treatment of overanticoagulated patients.  // American Family Physician;3/1/1996, Vol. 53 Issue 4, p1341 

    Reports on a study published in the 1995 issue of the `Chest' periodical by Glover and Morrill who compared the outcome of overanticoagulated patients who were treated with vitamin K with the outcome of patients who were treated conservatively. Methodology of the study; Research design.

  • Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin. Rondina, Matthew // ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p7 

    The article discusses whether oral vitamin K reduces risk for bleeding in patients with warfarin-associated coagulopathy. A randomized placebo-controlled trial was carried out in 14 anticoagulant centers in the U.S., Canada and Italy. The intervention, outcomes and patient follow up of the trial...

  • Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin. Crowther, Mark A.; Ageno, Walter; Garcia, David; Luqi Wang; Witt, Dan M.; Clark, Nathan P.; Blostein, Mark D.; Kahn, Susan R.; Vesely, Sara K.; Schulman, Sam; Kovacs, Michael J.; Rodger, Marc A.; Wells, Phillip; Anderson, David; Ginsberg, Jeffery; Selby, Rita; Siragusa, Sergio; Silingardi, Mauro; Dowd, Mary Beth; Kearon, Clive // Annals of Internal Medicine;3/3/2009, Vol. 150 Issue 5, p293 

    Background: Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain. Objective: To see whether low-dose oral vitamin K reduces bleeding events over 90 days in patients...

  • New Oral Anticoagulants: Targeted Inhibition of Factor Xa and Thrombin. Ciaccia, Antonio; Thai, John; Turpie, Alexander G. // Advances in Orthopaedics;Jun2010, Vol. 2 Issue 2, p52 

    Anticoagulants are recommended for the prevention and treatment of a wide spectrum of thromboembolic disorders. Recent developments in antithrombotic therapy have the potential to significantly impact the management of patients. Several direct thrombin and Factor Xa inhibitors are under...

  • Oral Vitamin K Corrects Warfarin Coagulopathy. Walling, Anne D. // American Family Physician;5/1/2001, Vol. 63 Issue 9, p1850 

    Discusses research on the effectiveness of vitamin K in treating warfarin-induced coagulopathy. Reference to a study led by M.A. Crowther which appeared in the November 4, 2000 issue of `Lancet'; Comparison between the active and passive approaches to treatment of warfarin-induced coagulopathy;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics